Stock Research: Medacta Group

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Medacta Group

SWX:MOVE CH0468525222
78
  • Value
    48
  • Growth
    89
  • Safety
    Safety
    13
  • Combined
    48
  • Sentiment
    91
  • 360° View
    360° View
    78
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Medacta Group SA is a Swiss-based medical device company specializing in orthopedic products and surgical techniques. The company operates in joint replacement, spine surgery, and sports medicine, offering hip, knee, shoulder, and spine products. It operates globally, providing training and support to healthcare professionals. In the last fiscal year, the company had a market cap of $3419 million, profits of $414 million, revenue of $611 million, and 1907 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 78 (better than 78% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Medacta Group are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Medacta Group. The consolidated Growth Rank has a good rank of 89, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 89% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 91, which means that professional investors are more optimistic about the stock than for 91% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 13, which means that the share price of Medacta Group is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 87% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 48, which means that the company has a financing structure that is riskier than those of 52% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
SPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 16-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
13 20 13 41
Growth
89 80 99 71
Safety
Safety
48 41 39 37
Sentiment
91 78 77 32
360° View
360° View
78 54 73 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
61 69 46 19
Opinions Change
74 84 79 92
Pro Holdings
n/a 65 59 47
Market Pulse
89 57 68 12
Sentiment
91 78 77 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
13 20 13 41
Growth
89 80 99 71
Safety Safety
48 41 39 37
Combined
48 45 52 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
23 21 21 44
Price vs. Earnings (P/E)
14 15 16 31
Price vs. Book (P/B)
12 6 1 14
Dividend Yield
34 44 43 49
Value
13 20 13 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
80 85 75 65
Profit Growth
77 81 91 64
Capital Growth
51 37 56 45
Stock Returns
83 62 91 69
Growth
89 80 99 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
36 39 40 26
Refinancing
37 34 31 33
Liquidity
71 75 56 52
Safety Safety
48 41 39 37

Similar Stocks

Discover high‑ranked alternatives to Medacta Group and broaden your portfolio horizons.

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

DKSH

SWX:DKSH
Country: Switzerland
Industry: Research & Consulting
Size: Large
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.